BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that it will report fourth quarter 2025 financial results on March 5, 2026, before the open of the U.S. financial markets. The company does not intend to hold a conference call. Additionally, Tango Therapeutics management is scheduled to participate in three upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston Corporate presentation on Wednesday, March 4 at 1:10-1:40 PM ETWebcast ...

Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companiesChief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on ...

PresentationI would now like to turn the conference over to Natasha Wagner. You may begin.Hello, and thank you for standing by. At this time, I would like to welcome everyone to the CareDx Investor Webinar Call. [Operator Instructions]Natasha Moshirian Wagner Hello, and thank you for joining us. I'm Natasha Wagner, VP of Corporate Communications at CareDx. Welcome to our investor webcast focused on AlloHeme, advancing AI-enabled relapse monitoring in AML and MDS post-cell therapy, positioning CareDx to lead ...

Core Insights - The FDA has provided regulatory clarity on INmune Bio's integrated Phase 2b/3 clinical development strategy for XPro1595 in early Alzheimer's Disease, confirming CDR-SB as the sole primary endpoint for registrational development [1][2][5] FDA Alignment Highlights - The FDA's feedback validates the enrichment-led design and primary endpoint, supporting the scientific and clinical strategy of the company [2][5] - The Phase 2b study will include approximately 300 participants over a nine-month evaluation period, utilizing the Early Mild Alzheimer's Cognitive Composite (EMACC) and plasma p-tau-217 as key measures [4][5] - CDR-SB will serve as the sole primary efficacy endpoint for the Phase 3 segment, aligning with its established role in Alzheimer's therapies [5][6] Integrated Phase 2b/3 Framework - The FDA indicated no objection to the integrated Phase 2b/3 design under a single master protocol, with the full program expected to enroll around 1,000 participants [5] - The Phase 3 portion will evaluate XPro1595 over an 18-month period [5] - An exploratory cohort of non-enriched early Alzheimer's patients will be included to assess broader effects, comprising approximately 20% of total enrollment [5] XPro™ Overview - XPro™ is a next-generation TNF inhibitor that selectively neutralizes soluble TNF, potentially reducing neuroinflammation and improving cognitive function in neurological diseases [8] Company Background - INmune Bio Inc. is a late-stage clinical biotechnology company focused on developing treatments targeting the innate immune system, with three product platforms including XPro™ [9]

Core Viewpoint - VolitionRx Limited is sponsoring a symposium at the European Hidradenitis Suppurativa Foundation Conference to present findings on the Nu.Q NETs assay, which aids in the management of Hidradenitis Suppurativa (HS) through a precision medicine approach [1][2][3]. Company Overview - VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for patients through earlier detection and monitoring of diseases [11][12]. - The company is developing cost-effective blood tests for various diseases, including cancers and conditions associated with NETosis, aiming to enhance patient quality of life [12]. Industry Context - Hidradenitis Suppurativa (HS) is a chronic condition affecting approximately 1% of the global population, characterized by painful skin abscesses and scarring [3][9]. - The condition is difficult to manage, and the introduction of biological treatments has shown varied responses among patients, highlighting the need for a precision medicine approach [4][9]. Product and Market Potential - The Nu.Q NETs assay is CE-Marked for clinical use in 27 EU member states and is positioned as a simple, low-cost test to detect diseases associated with NETosis, with a total addressable market estimated at $3.8 billion [6][8]. - The assay aims to classify HS patients and guide treatment decisions, potentially improving patient management and outcomes [4][6].

Core Insights - Tango Therapeutics, Inc. is participating in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026, at 2:00 PM EST, with CEO Malte Peters scheduled for a fireside chat [1] - The event will be accessible via a live webcast on the company's website, with a replay available for 90 days post-presentation [2] - Tango Therapeutics is focused on discovering novel drug targets and developing precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [3]

Core Viewpoint - Natera, Inc. has submitted a premarket approval (PMA) application to the U.S. FDA for its Signatera™ CDx, aimed at detecting molecular residual disease (MRD) in muscle-invasive bladder cancer (MIBC) patients who may benefit from atezolizumab treatment [1] Company Summary - Natera, Inc. is recognized as a global leader in cell-free DNA and precision medicine [1] - The PMA submission is backed by data from a randomized, double-blind, phase 3 clinical trial known as IMvi [1]

Core Insights - Bio-Techne Corporation has launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform, enhancing capabilities for neurodegenerative disease research [1][4]. Group 1: Product Launch and Features - The new assays provide step-change improvements in analytical sensitivity and reliable quantification of biomarkers such as NFL, GFAP, pTau 217, and Amyloid (aa1-42) [2][4]. - The Ella platform allows for femtogram-level detection, enabling precise quantification of low-abundance biomarkers that are often undetectable by conventional methods [4][5]. - The automated workflow of Ella reduces manual steps and variability, achieving an overall runtime of under three hours for assay results [4][7]. Group 2: Research Impact and Adoption - The assays facilitate the detection of subtle biological changes, accelerating insights into disease onset, progression, and treatment response [3][4]. - Ella has been cited in over 200 peer-reviewed publications focused on neurology, demonstrating its widespread adoption in translational and clinical research [3][5]. - Bio-Techne's immunoassay leadership is strengthened by combining ultrasensitive assays with automated instrumentation, improving reproducibility and data quality [5]. Group 3: Company Overview - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people globally [6]. - The company provides innovative tools and bioactive reagents for research and clinical diagnostics, with a broad portfolio that drives breakthroughs in neuroscience research and precision medicine [6][5].

Core Insights - Opus Genetics, Inc. has launched a clinical trial for a gene therapy targeting MERTK-related retinitis pigmentosa, a rare inherited eye disease that leads to progressive vision loss and blindness [1][3][4] Company Overview - Opus Genetics is a clinical-stage biopharmaceutical company focused on developing gene therapies aimed at restoring vision and preventing blindness in patients with inherited retinal diseases (IRDs) [6][8] - The company is working on a pipeline that includes seven AAV-based programs, with OPGx-MERTK being a key candidate for MERTK-related retinitis pigmentosa [6][8] Clinical Trial Details - The clinical trial will assess the safety and efficacy of OPGx-MERTK, which uses an adeno-associated virus (AAV) to deliver a functional copy of the MERTK gene to retinal cells [3][4] - The trial is set to begin in 2026 at Cleveland Clinic Abu Dhabi, which will serve as the clinical site [2][7] Collaboration and Impact - The trial is being conducted in collaboration with the Department of Health – Abu Dhabi, Cleveland Clinic Abu Dhabi, and other local partners, highlighting Abu Dhabi's commitment to precision medicine and rare disease innovation [2][5] - MERTK-related retinitis pigmentosa affects approximately 60,000 patients globally, and this trial represents a significant opportunity to address an unmet medical need [4][7]

Core Insights - Natera, Inc. has announced the publication of a new prospective clinical trial in Transplantation Direct, focusing on donor-derived cell-free DNA (dd-cfDNA) surveillance [1] - The study was conducted by The Ohio State University Wexner Medical Center (OSU-WMC) to evaluate whether Prospera-guided monitoring can reduce the number of invasive biopsies for patients [1] Company Overview - Natera, Inc. is recognized as a global leader in cell-free DNA and precision medicine [1] - The company is actively involved in advancing non-invasive monitoring techniques in the field of transplantation [1] Industry Context - The trial aims to enhance patient care by potentially minimizing the need for invasive procedures, which is a significant concern in transplantation medicine [1] - The use of dd-cfDNA surveillance represents a growing trend in precision medicine, emphasizing the importance of non-invasive diagnostic methods [1]